<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074889</url>
  </required_header>
  <id_info>
    <org_study_id>FRGS/1/2018/SKK02/UKM/03/2</org_study_id>
    <nct_id>NCT04074889</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Fatty Liver</brief_title>
  <official_title>Study of the Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Non-alcoholic Fatty Liver Disease: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B-Crobes Laboratory Sdn. Bhd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fibronostics Pte. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Education, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatty liver has been associated with high risk of progression to inflammation of the liver,&#xD;
      liver cirrhosis (hardening of the liver), and eventually can lead to liver cancer. So far,&#xD;
      the treatment for this condition involves controlling the cholesterol level in the body by&#xD;
      practicing low fat diet and daily exercise. However, recently there has been evidence that&#xD;
      alteration of the normal population of various types of bacteria that lives in the intestines&#xD;
      may contributes to the development of fatty liver.&#xD;
&#xD;
      Probiotics is a dietary supplement containing live bacteria that is formulated to change the&#xD;
      composition and population of the bacteria in the intestines. It is postulated that by taking&#xD;
      specifically formulated probiotics, the alteration of the intestinal bacteria may lead to&#xD;
      improvement of the fatty liver, leading to better daily liver function.&#xD;
&#xD;
      In this 6-month study, investigators would like to investigate the effectiveness of the&#xD;
      probiotics in improving the liver function and in the treatment of the fatty liver. It will&#xD;
      compare the fatty liver of patients who took the probiotics supplements compared to those who&#xD;
      did not took it and see if there is any improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver&#xD;
      disease nowadays. NAFLD is considered as the hepatic manifestation of metabolic syndrome. In&#xD;
      Malaysia, the prevalence of metabolic disorders such as diabetes mellitus, obesity and&#xD;
      dyslipidemia are increasing with time. Despite the disease burden, treatments for NAFLD are&#xD;
      currently limited due to the ongoing evolving theory of its pathogenesis.&#xD;
&#xD;
      One of the proposed mechanisms is via gut-liver axis (GLA), whereby the role of gut&#xD;
      microbiota has been implicated. Two main components of GLA are gut microbiota and gut&#xD;
      barrier. A change in gut microbiota composition will predispose to gut barrier dysfunction,&#xD;
      which subsequently leads to bacterial by-products translocation into the portal circulation.&#xD;
      Eventually, these by-products reach the liver and trigger the cascades of hepatic&#xD;
      inflammation, leading to fatty liver and its disease progression.&#xD;
&#xD;
      The aim of this study is to investigate the role of probiotics in modulating the gut&#xD;
      microenvironment - namely gut microbiota composition, gut barrier function and local gut&#xD;
      inflammation, as well as its effect on the clinical outcomes in NAFLD patients.&#xD;
&#xD;
      Investigators propose a randomised, double-blind, placebo-controlled trial of 6-month&#xD;
      duration. Investigators aim to recruit 48 NALFD patients, with either treated with probiotics&#xD;
      or placebo. Small intestinal microbiota will be determined by 16S-rRNA sequencing and&#xD;
      immunoreactivity of zona occludens-1 (tight junction protein in the gut barrier) and&#xD;
      cytokines mRNA level will be measured. The degree of liver steatosis and stiffness will be&#xD;
      assessed by using transient elastography and biochemical blood tests. All these variables&#xD;
      will be determined pre- and post-intervention with probiotics/placebo.&#xD;
&#xD;
      This study will provide a valuable knowledge on the role of probiotics as the gut&#xD;
      microenvironment modulator and strengthen the hypothesis of GLA involvement in the NAFLD&#xD;
      development. Hence, probiotics can be strongly considered as one of the treatment options for&#xD;
      non-alcoholic fatty liver disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double-blind, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in hepatic steatosis score</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>as measured by Controlled Attenuated Parameter score from Transient Elastography (Fibroscan)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference in hepatic fibrosis score</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>as measured by liver stiffness score from Transient Elastography (Fibroscan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in hepatic steatosis, inflammation and fibrosis scores</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>as measured by 10 serum biomarkers (LiverFASt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition of small intestine</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>assessed by 16rRNA Amplicon Sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference of immunoreactivity score of zona occludens-1 (ZO-1: indicator of intestinal permeability) and CD4+,CD8+, IL-8 (indicator of intestinal mucosal immune system).</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>Immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in mRNA expression of genes related to inflammation (IL-6, TNF-alpha, IFN-gamma)</measure>
    <time_frame>6-7 months post supplementation</time_frame>
    <description>Measured by serum qPCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given Lactobacillus &amp; Bifidobacterium containing probiotics [Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg], to be taken 1 sachet twice daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>(Microbial cell preparation) Probiotics</intervention_name>
    <description>Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Hexbio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sachet with no microbial cell preparation</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and above 2. Diagnosis of NAFLD is confirmed by the presence of fatty liver&#xD;
             detected by abdominal ultrasound and controlled attenuation parameter (CAP) score from&#xD;
             FibroScan® of &gt;263 3. Raised ALT level (above upper limit of normal): &gt; 35IU/L for&#xD;
             males and &gt; 25 IU/L for females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of other chronic liver diseases (as determined by clinical and standard&#xD;
             investigations) - e.g. Hepatitis B, C infections, autoimmune hepatic disorders.&#xD;
&#xD;
          2. Evidence of acute disorders that affecting the liver - e.g. drug induced liver injury,&#xD;
             non-Hepatitis B, C viral infection.&#xD;
&#xD;
          3. Biliary disease.&#xD;
&#xD;
          4. Liver cancer - primary hepatocellular carcinoma or liver metastasis.&#xD;
&#xD;
          5. Evidence of liver cirrhosis.&#xD;
&#xD;
          6. Alcohol intake &gt; 20g/day for males and &gt;10g/day for females.&#xD;
&#xD;
          7. Use of steatogenic medications within the past one months - e.g. systemic steroids,&#xD;
             methotrexate.&#xD;
&#xD;
          8. History of bariatric surgery&#xD;
&#xD;
          9. Intake of antibiotics and/or probiotic and proton pump inhibitor within one month&#xD;
             before the start of the study or during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khairul Najmi Muhammad Nawawi, MBBCh BAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Malaysia Medical Centre, Kuala Lumpur, Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khairul Najmi Muhammad Nawawi, MBBCh BAO</last_name>
    <phone>+60183734807</phone>
    <email>khairulnajmi84@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khairul Najmi Muhammad Nawawi, MBBCh BAO</last_name>
      <phone>0060183734807</phone>
      <email>khairulnajmi84@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohamad Hizami Mohamad Nor, MBBCh BAO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurainina Ayob, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raja Affendi Raja Ali, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norfilza Mohd Mokhtar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geok Chin Tan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhiqin Wong, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Kebangsaan Malaysia Medical Centre</investigator_affiliation>
    <investigator_full_name>Khairul Najmi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Gut Liver Axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

